Drug delivery to the central nervous system (CNS) remains a challenge in neuro-oncology.
Despite decades of research in this field, no consensus has emerged as to the best …

Targeted radionuclide therapy has become increasingly prominent as a nuclear medicine
subspecialty. For many decades, treatment with radionuclides has been mainly restricted to …

Oncologic nuclear medicine has come to a fork in the road, with the choice being whether to
remain a peripheral diagnostic lesion-detection technique competing against the ever …

Despite decades of laboratory investigation and promising chemotherapy responses shown
in xenograft models, survival for patients with central nervous system (CNS) tumors remains …

The central nervous system (CNS) may be considered as a sanctuary site, protected from
systemic chemotherapy by the meninges, the cerebrospinal fluid (CSF) and the blood-brain …

American Society of Clinical Oncology (ASCO), the largest clinical oncology meeting in the
USA, meets annually and consistently provides an exciting forum to present new cancer …

According to WHO, cancer is the second leading cause of death worldwide [1]. While some
cancers are treatable and considered less life threatening if detected at an early stage …

The fifth quadrennial World Federation of Neuro-Oncology Societies (WFNOS) Meeting was
held in Zurich, Switzerland from May 4–7, 2017, and was attended by 917 participants from …

The use of nanoparticles to improve the distribution and extend the duration of exposure to
therapy continues to be investigated and applied in cancer research and treatment …

Drug delivery to the central nervous system (CNS) remains a challenge in neuro-oncology.
Despite decades of research in this field, no consensus has emerged as to the best …